Stryker Corporation
SYK
$305.51
+1.13%
Stryker Corporation is a leading global medical technology company that designs, manufactures, and markets a comprehensive array of medical equipment, instruments, and implantable devices, operating within the Medical Devices industry. The company is a dominant player, holding one of the top three positions in reconstructive orthopedic implants and the leadership position in operating room equipment, establishing itself as a diversified and entrenched market leader. The current investor narrative is focused on navigating a challenging period marked by a significant stock price decline, with recent attention likely centered on evaluating the company's resilience in its core orthopedic and MedSurg segments, its ability to sustain growth and margins amidst broader market pressures, and its strategic positioning for a recovery.…
SYK
Stryker Corporation
$305.51
Related headlines
Investment Opinion: Should I buy SYK Today?
Rating & Thesis: Hold. Stryker is a high-quality business caught in a severe market downdraft; investors should wait for technical stabilization or a clearer fundamental catalyst before initiating new positions, despite the attractive valuation on a forward basis.
Supporting Evidence: The forward P/E of 17.60x is compelling for a company with 11.4% revenue growth and a 12.9% net margin. The company's financial health is excellent, with a debt-to-equity of 0.66, a current ratio of 1.89, and $4.28 billion in TTM free cash flow. However, these strengths are counterbalanced by the powerful technical downtrend, with the stock down over 20% in 3 months and testing its 52-week low, indicating persistent selling pressure that may not be over.
Risks & Conditions: The two biggest risks are 1) a break below the $294.55 support level extending the downtrend, and 2) a growth deceleration that invalidates the forward earnings estimates underpinning the 17.6x P/E. This Hold rating would upgrade to a Buy on a confirmed technical reversal (e.g., a weekly close above $340) coupled with sustained double-digit revenue growth. It would downgrade to a Sell on a decisive break below $294 with high volume, or if quarterly revenue growth falls below 8%. The stock appears fairly valued to slightly undervalued on forward earnings but remains overvalued on a trailing basis, reflecting a market in transition between punishing past multiples and pricing in a recovery.
Sign up to view all
SYK 12-Month Price Forecast
Stryker presents a classic clash between deteriorating price action and resilient underlying business metrics. The forward valuation is attractive, and the company's financial health is impeccable. However, the technical picture is severely damaged, and the stock is acting as a high-beta proxy in a risk-off environment. The most likely path (50% probability) is a base-case scenario of volatile sideways action as the market digests the valuation reset. The stance would upgrade to Bullish on a confirmed technical reversal above $340 with volume, indicating the fundamental story is regaining control. It would downgrade to Bearish on a weekly close below $290, signaling the breakdown has further to run.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $397.16 and implied upside of +30.0% versus the current price.
Average Target
$397.16
16 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
16
covering this stock
Price Range
$244 - $397
Analyst target range
The stock is covered by 13 analysts, indicating substantial institutional interest. Specific Buy/Hold/Sell distribution, consensus recommendation, and average target price data are not provided in the dataset. Therefore, the implied upside or downside to a consensus target cannot be calculated. The provided institutional ratings show a mix of actions, with recent notes including a 'Market Outperform' upgrade from Citizens in December 2025 and maintained 'Buy' or 'Outperform' ratings from firms like Needham, BTIG, and Bernstein in early 2026, suggesting underlying analyst confidence despite the stock's weak price performance. The absence of a clear downgrade trend in the recent data, coupled with the high analyst count, suggests coverage remains stable, but the wide target price range typical for analyst coverage signals there is debate and uncertainty regarding the stock's near-term path, likely tied to the timing and magnitude of a potential operational and stock price recovery.
Bulls vs Bears: SYK Investment Factors
The bull case is anchored in Stryker's demonstrably strong fundamentals: double-digit revenue growth, exceptional profitability, robust cash flow, and a fortress balance sheet. The bear case is driven almost entirely by technical and sentiment factors: a severe, accelerating downtrend, extreme relative underperformance, and valuation compression in a risk-off market for growth stocks. Currently, the bearish technical momentum presents stronger near-term evidence, as price action trumps fundamentals in the short term. The single most important tension in the investment debate is whether the company's robust operational performance (11.4% revenue growth, 12.9% net margin) can eventually overcome the powerful negative market sentiment and technical breakdown that has driven the stock to its 52-week low.
Bullish
- Strong Double-Digit Revenue Growth: Q4 2025 revenue grew 11.42% YoY to $7.171 billion, demonstrating robust demand in both Orthopaedics and MedSurg segments. This growth rate is healthy for a large-cap medtech firm and indicates underlying business momentum despite stock price weakness.
- Exceptional Profitability and Cash Flow: The company boasts a trailing net margin of 12.92%, a gross margin of 63.96%, and generated $4.283 billion in TTM free cash flow. This strong cash generation provides ample internal funding for dividends, buybacks, and strategic M&A to fuel future growth.
- Valuation Compression Creates Opportunity: The forward P/E of 17.60x is significantly lower than the trailing P/E of 41.38x, reflecting market expectations for a sharp earnings rebound. The stock price at $294.73 is just above its 52-week low of $294.55, suggesting significant pessimism is already priced in.
- Healthy Balance Sheet and Liquidity: Stryker maintains a strong balance sheet with a debt-to-equity ratio of 0.66 and a current ratio of 1.89. This financial stability provides resilience during market downturns and flexibility for strategic investments.
Bearish
- Severe Technical Downtrend and Underperformance: The stock is down 21.19% over the past year and 20.25% over the past 3 months, significantly underperforming the S&P 500 by over 50 percentage points on a 1-year basis. It is currently testing its 52-week low, with a break below signaling further potential downside.
- Elevated Trailing Valuation Despite Decline: A trailing P/E of 41.38x remains high on an absolute basis, even after the price decline. This valuation is predicated on a high-growth narrative that is being severely tested by the market's recent repricing of medtech stocks.
- High Volatility and Market Correlation Risk: The stock's severe underperformance (-20.51% relative strength vs. SPY over 1 month) indicates it is being treated as a high-beta, high-growth name in a risk-off environment. This exposes it to further multiple compression if interest rate or macro concerns persist.
- Potential for Growth Deceleration: While Q4 growth was strong, the stock's price action suggests the market fears a slowdown. The PEG ratio of 5.16 indicates the market prices in very high future growth; any disappointment in forward guidance could trigger another leg down.
SYK Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -21.19% and a 6-month decline of -17.27%. As of the latest close at $294.73, the price is trading near the bottom of its 52-week range, at just 73% of the distance from its 52-week low of $294.55 to its high of $404.87, indicating the stock is at a critical technical juncture and may be perceived as a deep value opportunity or a falling knife depending on fundamental catalysts. Recent momentum remains sharply negative and is accelerating the longer-term downtrend, with a 3-month decline of -20.25% and a 1-month drop of -10.53%, significantly underperforming the S&P 500 which gained 9.98% over the past month, as evidenced by a severe relative strength reading of -20.51. This persistent weakness culminated in a sharp breakdown below key support levels in late March and April, with the stock now testing its 52-week low of $294.55. A decisive break below this level would signal a continuation of the bearish trend, while a hold and reversal could indicate a potential double-bottom formation. The stock's high volatility relative to the market is a key risk consideration for investors.
Beta
0.81
0.81x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$281-$405
Price range past year
Annual Return
-20.9%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | -11.7% | +7.7% |
| 3m | -16.5% | +9.7% |
| 6m | -15.7% | +11.3% |
| 1y | -20.9% | +27.3% |
| ytd | -12.3% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $7.171 billion representing an 11.42% year-over-year increase, and the business is diversified with Orthopaedics ($4.964B) and MedSurg ($4.562B) segments contributing nearly equally. This double-digit growth trajectory is healthy for a large-cap medtech firm, though sequential trends from the provided quarterly data show some variability, with Q4 revenue up significantly from Q3's $6.057 billion. The company is highly profitable, posting a Q4 2025 net income of $849 million and a trailing net margin of 12.92%, supported by strong gross margins of 63.96% and an operating margin of 19.47%. Profitability metrics are solid, with a Return on Equity of 14.48% and a Return on Assets of 7.88%. The balance sheet is healthy with a manageable debt-to-equity ratio of 0.66 and a strong current ratio of 1.89, indicating good liquidity. Cash flow generation is a key strength, with trailing twelve-month free cash flow of $4.283 billion, providing ample internal funding for growth initiatives, dividends, and potential acquisitions.
Quarterly Revenue
$7.2B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.65%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Given the company's consistent profitability with a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. Stryker's trailing PE ratio is 41.38x, while its forward PE is notably lower at 17.60x, indicating the market expects a significant rebound in earnings over the next year. Compared to sector averages (data not available in the provided set), we cannot quantify a premium or discount, but a trailing PE above 40x suggests a high valuation relative to historical market norms, which is likely predicated on its quality and growth profile. Historically, the stock's own trailing PE has fluctuated significantly, ranging from approximately 24.9x at the end of 2023 to over 62.8x at the end of 2024. The current reading of 41.38x sits above the lower end of this multi-year range but well below the peaks, suggesting the recent price decline has compressed the valuation from previously elevated levels, though it remains rich on an absolute basis, pricing in expectations of a earnings recovery.
PE
41.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 23x~78x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Stryker's primary financial risk is not insolvency—its balance sheet is strong—but rather valuation risk tied to its earnings multiple. The trailing P/E of 41.38x, though compressed from highs above 62x, remains elevated and depends on sustained high growth to justify it. Any deceleration from the current 11.4% YoY revenue growth rate could trigger significant multiple contraction. Furthermore, while diversified, the company's revenue is concentrated in two cyclical segments (Orthopaedics and MedSurg), making it susceptible to procedure volume fluctuations driven by hospital spending or economic conditions.
Market & Competitive Risks: The stock faces acute market risk from its high volatility and correlation to growth stock sentiment, as evidenced by its -50.23 percentage point underperformance versus the S&P 500 over the past year. Trading at a forward P/E of 17.6x, it may still be vulnerable to further compression if sector-wide de-rating continues. Competitive risks are inherent but mitigated by its top-three position in orthopedics and leadership in OR equipment. However, innovation from peers or pricing pressure could threaten its premium margins, which are currently a robust 64.0% gross and 19.5% operating.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current bearish momentum, where deteriorating sector sentiment combines with a company-specific earnings miss or guidance cut. This could break the critical support at the 52-week low of $294.55, triggering algorithmic selling and a loss of investor confidence. A realistic downside could see the stock re-test levels implied by a forward P/E in the low teens (e.g., 14-15x), suggesting a potential decline of 15-20% from the current price, translating to a range of $235-$250. This would represent a total peak-to-trough drawdown exceeding 40% from the 52-week high of $404.87.
FAQ
The key risks are: 1) Technical/Momentum Risk: The stock is in a severe downtrend (-21.2% over 1 year) and a break below $294.55 could trigger further declines. 2) Valuation Compression Risk: The high trailing P/E of 41.38x is vulnerable if growth slows. 3) Sector Sentiment Risk: Medtech stocks are under pressure, as seen with peer sell-offs, which can overshadow strong company results. 4) Execution Risk: Any stumble in maintaining double-digit revenue growth or premium margins (64.0% gross) could severely impact the stock given current high expectations embedded in the forward multiple.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $320 and $360 as it consolidates, supported by its forward P/E of ~17-18x and high-single-digit growth. The Bull Case (30% probability) targets a recovery to $380-$405 on sustained double-digit growth and improved sector sentiment. The Bear Case (20% probability) warns of a drop to $250-$295 if support breaks and growth disappoints. The most likely outcome is the Base Case, assuming the company executes well but the stock remains range-bound as it works off oversold conditions.
SYK's valuation is bifurcated. On a trailing basis, with a P/E of 41.38x, it appears overvalued relative to broad market norms. However, the forward P/E of 17.60x suggests the market expects significant earnings growth and prices the stock more reasonably. Compared to its own historical P/E range (approximately 25x to 63x), the current trailing multiple is in the middle, while the forward multiple is near the lower end. This implies the stock is fairly valued to slightly undervalued if forward earnings estimates are met, but the high trailing multiple indicates it is still pricing in a premium for its quality and growth profile.
SYK is a good stock for patient, long-term investors who can look past severe near-term volatility. The forward P/E of 17.6x is reasonable for a company growing revenue at 11.4% with a 12.9% net margin and a fortress balance sheet. However, it is not a good buy for short-term traders or the risk-averse, as the stock is in a powerful downtrend, testing its 52-week low, and has underperformed the market by over 50 percentage points in the past year. The ideal entry point would be on a confirmed technical reversal, reducing the risk of catching a 'falling knife.'
SYK is unequivocally suitable for long-term investment, not short-term trading. Its strong fundamentals—market leadership, high profitability, and robust cash flow—are tailwinds for compounding over years. However, its high volatility, negative momentum, and sensitivity to market sentiment make it treacherous for short-term positions. The severe underperformance versus the market (-20.5% in the past month alone) highlights this volatility. Investors should have a minimum horizon of 3-5 years to allow the company's operational strengths to overcome the current technical and sentiment headwinds.